Eligard Kit is a drug owned by Tolmar Inc. It is protected by 14 US drug patents filed from 2013 to 2024. Out of these, 2 drug patents are active and 12 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 22, 2041. Details of Eligard Kit's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US11931559 | Systems and methods for mixing syringe valve assemblies |
Dec, 2041
(17 years from now) | Active |
| US11771841 | Systems and methods for mixing syringe valve assemblies |
Dec, 2041
(17 years from now) | Active |
| US8470359 | Sustained release polymer |
Oct, 2023
(1 year, 2 months ago) |
Expired
|
| US9539333 | Sustained release polymer |
Nov, 2020
(4 years ago) |
Expired
|
| US9914802 | Sustained release polymer |
Nov, 2020
(4 years ago) |
Expired
|
| US9254307 | Polymeric delivery formulations of leuprolide with improved efficacy |
Oct, 2018
(6 years ago) |
Expired
|
| US9283282 | Sustained release polymer |
Oct, 2018
(6 years ago) |
Expired
|
| US8486455 | Polymeric delivery formulations of leuprolide with improved efficacy |
Oct, 2018
(6 years ago) |
Expired
|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8840916 | Sustained release polymer |
Nov, 2020
(4 years ago) |
Expired
|
| US6626870 | Stoppering method to maintain sterility |
Mar, 2020
(4 years ago) |
Expired
|
| US6565874 | Polymeric delivery formulations of leuprolide with improved efficacy |
Oct, 2018
(6 years ago) |
Expired
|
| US6773714 | Polymeric delivery formulations of leuprolide with improved efficacy |
Oct, 2018
(6 years ago) |
Expired
|
| US5599552 | Biodegradable polymer composition |
Feb, 2014
(10 years ago) |
Expired
|
| US6395293 | Biodegradable implant precursor |
Sep, 2013
(11 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Eligard Kit's patents.
Latest Legal Activities on Eligard Kit's Patents
Given below is the list of recent legal activities going on the following patents of Eligard Kit.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Change in Power of Attorney (May Include Associate POA) Critical | 24 Apr, 2024 | US11931559 |
| Change in Power of Attorney (May Include Associate POA) Critical | 24 Apr, 2024 | US11771841 |
| Email Notification Critical | 24 Apr, 2024 | US11931559 |
| Email Notification Critical | 24 Apr, 2024 | US11771841 |
| Recordation of Patent eGrant | 19 Mar, 2024 | US11931559 |
| Patent eGrant Notification | 19 Mar, 2024 | US11931559 |
| Mail Patent eGrant Notification | 19 Mar, 2024 | US11931559 |
| Patent Issue Date Used in PTA Calculation Critical | 19 Mar, 2024 | US11931559 |
| Email Notification Critical | 19 Mar, 2024 | US11931559 |
| Recordation of Patent Grant Mailed Critical | 19 Mar, 2024 | US11931559 |
Several oppositions have been filed on Eligard Kit's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Eligard Kit's generic, the next section provides detailed information on ongoing and past EP oppositions related to Eligard Kit patents.
Eligard Kit's Oppositions Filed in EPO
Eligard Kit has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 23, 2013, by Generics [Uk] Limited. This opposition was filed on patent number EP09012462A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP09012462A | Oct, 2013 | Generics [UK] Limited | Revoked |
US patents provide insights into the exclusivity only within the United States, but Eligard Kit is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Eligard Kit's family patents as well as insights into ongoing legal events on those patents.
Eligard Kit's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Eligard Kit's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 22, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Eligard Kit Generic API suppliers:
Leuprolide Acetate is the generic name for the brand Eligard Kit. 8 different companies have already filed for the generic of Eligard Kit, with Amneal having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Eligard Kit's generic
Alternative Brands for Eligard Kit
Eligard Kit which is used for treating cancer, specifically palliative treatment of prostate cancer., has several other brand drugs in the same treatment category and using the same active ingredient (Leuprolide Acetate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Abbvie Endocrine Inc |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Leuprolide Acetate. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Abbvie Endocrine |
| |
| Abbvie Endocrine Inc |
| |
| Invagen Pharms |
| |
| Ortho Mcneil Janssen |
| |
| Tolmar |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Leuprolide Acetate, Eligard Kit's active ingredient. Check the complete list of approved generic manufacturers for Eligard Kit
About Eligard Kit
Eligard Kit is a drug owned by Tolmar Inc. It is used for treating cancer, specifically palliative treatment of prostate cancer. Eligard Kit uses Leuprolide Acetate as an active ingredient. Eligard Kit was launched by Tolmar in 2004.
Approval Date:
Eligard Kit was approved by FDA for market use on 14 December, 2004.
Active Ingredient:
Eligard Kit uses Leuprolide Acetate as the active ingredient. Check out other Drugs and Companies using Leuprolide Acetate ingredient
Treatment:
Eligard Kit is used for treating cancer, specifically palliative treatment of prostate cancer.
Dosage:
Eligard Kit is available in powder form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 45MG | POWDER | Prescription | SUBCUTANEOUS |
| 22.5MG | POWDER | Prescription | SUBCUTANEOUS |
| 7.5MG | POWDER | Prescription | SUBCUTANEOUS |
| 30MG | POWDER | Prescription | SUBCUTANEOUS |